EGFR and non-small cell lung carcinoma: NSCLC patients harboring these sensitizing EGFR mutations were exceptionally sensitive to the reversible first-generation EGFR TKIs (gefitinib and erlotinib) and the irreversible second-generation EGFR TKIs (afatinib and dacomitinib) [5, 6].